(4-((4-(Tert-Butoxycarbonyl)piperazin-1-yl)methyl)phenyl)boronic acid cas: 1190095-10-3

CAS NO: 1190095-10-3
(4-((4-(Tert-Butoxycarbonyl)piperazin-1-yl)methyl)phenyl)boronic acid cas: 1190095-10-3
Description Review

Some compounds are more notable than others in the field of chemical research and pharmaceutical development because of their distinctive structures and prospective uses. 4-((4-(Tert-Butoxycarbonyl)piperazin-1-yl)methyl)phenyl)boronic acid is one such chemical. The chemical in question has attracted interest across multiple disciplines owing to its unique attributes and prospective applications.

Trending Search:
A compound called 4-Tert-Butoxycarbonyl piperazine boronic acid is being referred to.
CAS 1190095-10-3 is the chemical compound known as piperazine boronic acid.
Phenylboronic acid derivatives,
Exploring the fascinating world of boronic acid compounds in pharmaceuticals,
Exploring piperazine-based boronic acids.

Other products in the same market:
This substance is in a special group because of the way its chemicals are structured. When it comes to specific uses, however, other boronic acids and piperazine derivatives might be better options.

Benefits for your well-being:
It seems that the primary emphasis of this particular molecule is on research and pharmaceutical development rather than on direct therapeutic use, which means that the health advantages of this particular component are not widely recognized. However, molecules with comparable structures have been investigated for drug production and pharmaceutical intermediates.

Possible Consequences:
This compound's possible effects are mostly dependent on how it is used in pharmaceutical research. It might be employed in the manufacture of numerous medications or in more sophisticated chemical processes.

Explanation of Product Mechanism:
Its mechanism may involve the formation of reversible covalent complexes with diols and other polyols, a characteristic behavior of boronic acids, given that it is a boronic acid derivative. In many chemistry and biological situations, this trait can be useful.

Ensuring safety:
There is a lack of comprehensive documentation about the safety profile of this substance in publically accessible sources. As is the case with many other research compounds, it need to be handled with caution and in accordance with the usual safety regulations of the laboratory.

Possible Adverse Reactions:
The biological negative effects of this research compound remain unknown. To prevent exposure, handling must be done with the proper safety precautions.

Information on dosing:
Because this chemical is not utilized as a prescription medicine, there is no standard dose information available. Its application is limited to laboratory and research environments.

Important Note:
Because it is a study drug, there are no specific warnings about when it shouldn't be used. Nevertheless, it is important to follow normal measures to prevent any improper usage or handling.

In summary:
Chemical research and pharmaceutical development may benefit from 4-((4-(Tert-Butoxycarbonyl)piperazin-1-yl)methyl)phenyl)boronic acid. Numerous scientific investigations are interested in it because of its distinctive structure. While its direct health advantages are unknown, its involvement in the production of more complex chemicals may be important. As with any chemical used in scientific research, it must be handled with care in accordance with all safety protocols.

Additional Questions:
Can you tell me 4-((4-(Tert-Butoxycarbonyl)piperazin-1-yl)methyl)phenyl)boronic acid's principal application?
To begin, its principal use is in the field of chemical research and the creation of pharmaceuticals, namely as an intermediary in the process of synthesising more complicated molecules.

(4-((4-(Tert-Butoxycarbonyl)piperazin-1-yl)methyl)phenyl)boronic acid cas: 1190095-10-3
Does this chemical have medicinal uses?
A: This chemical is not being used directly in any medical therapies at this time. Its function is more closely related to research and as a possible intermediary in medication manufacturing.

What precautions should be observed when working with this chemical substance?
A: Standard safety rules for the lab should be followed, such as wearing gloves and safety glasses and working with it in a well-ventilated area or fume hood.

Is this substance known to be harmful in any way?
Because this compound is largely used for research purposes, there is a lack of widely accessible information on its toxicity. Until proved otherwise, it should be treated as harmful.

  • 4-(4-t-BOC-Piperazinomethyl)phenylboronic acid,
  • Suzuki-Miyaura cross-coupling,
  • t-BOC protecting group in organic synthesis,
  • Boronic acid applications in medicinal chemistry,
  • Carbon-carbon bond formation in pharmaceuticals,
  • Piperazine ring in drug synthesis,
  • Organic solvents for phenylboronic compounds,
  • Safety handling of boronic acid derivatives,
  • Amine protection with t-BOC,
  • Biologically active molecule synthesis.

Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe